Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persistence of Immune Response of Twinrix Adult in Adolescents
NCT00197171Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2003
- Primary completion
- Dec 2003
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hepatitis b vaccine recombinant in hepatitis A (HAV) and hepatitis B (HBV) (2 arms), sponsored by GSK. Primary endpoints: Immune persistence in terms of anti-HAV antibodies and GMCs at 6 years and Immune persistence in terms of anti-HBs antibodies and GMCs at 6 years. Started Sep 2003; status: completed.
02
Drugs
hepatitis b vaccine recombinant
03
Conditions
hepatitis A (HAV)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00197171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00197171.